- Notification that Annual Report will be submitted late (NT 10-K)
31 Marzo 2010 - 8:23AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 12b-25
NOTIFICATION
OF LATE FILING
SEC File
Number: 001-33537
CUSIP
Number: 16941X 10 5
|
|
|
|
|
|
|
|
|
(Check
one):
|
|
þ
Form 10-K
o
Form 20-F
o
Form 11-K
o
Form 10-Q
o
Form 10-D
o
Form N-SAR
o
Form N-CSR
|
|
|
|
|
|
|
|
|
|
|
|
|
For
Period Ended:
|
|
December
31, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-K
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 20-F
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 11-K
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form 10-Q
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o
Transition Report on Form N-SAR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
the Transition Period Ended:
|
|
|
|
|
|
|
|
|
|
|
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART I — REGISTRANT
INFORMATION
China
Shenghuo Pharmaceutical Holdings, Inc.
No. 2,
Jing You Road, Kunming National Economy & Technology Developing
District
People’s
Republic of China 650217
PART II — RULES 12b-25(b) AND
(c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
|
|
|
|
|
þ
|
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
|
|
|
|
þ
|
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or
Form N-CSR, or portion thereof, will be filed on or before the
fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject
distribution report on Form 10-D, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due date;
and
|
|
|
|
|
|
|
|
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR,
or the transition report or portion thereof, could not be filed within the
prescribed time period.
Until recently, we lacked sufficient
financial resources to commence the preparation of our financial
statements for the year ended December 31, 2009, which resulted in a delay in
the commencement of our audit. As a result, we are unable to file our
Annual Report on Form 10-K in a timely manner without unreasonable effort or
expense. We are seeking to file the report within the extension
period provided under Rule 12b-25.
PART IV — OTHER
INFORMATION
|
(1)
|
|
Name and telephone number of
person to contact in regard to this notification
|
|
|
|
|
|
|
|
Gui
Hua Lan, Chief Executive Officer and Chairman of the
Board
|
Phone: 0086-871-728-2628
|
|
|
|
|
|
|
(2)
|
|
Have all other periodic reports
required under Section 13 or 15(d) of the Securities Exchange Act of
1934 or Section 30 of the Investment Company Act of 1940 during the
preceding 12 months or for such shorter period that the registrant
was required to file such report(s) been filed? If answer is no, identify
report(s).
|
|
|
|
Yes
þ
No
o
|
|
|
|
|
|
(3)
|
|
Is it anticipated that any
significant change in results of operations from the corresponding period
for the last fiscal year will be reflected by the earnings statements to
be included in the subject report or portion
thereof?
|
|
|
|
Yes
o
No
þ
|
|
|
|
|
|
|
|
|
|
|
|
If so, attach an explanation of
the anticipated change, both narratively and quantitatively, and, if
appropriate, state the reasons why a reasonable estimate of the results
cannot be made.
|
|
|
|
|
CHINA
SHENGHUO PHARMACEUTICAL HOLDINGS, INC. has caused this notification to be signed
on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
Date: March
31, 2010
|
By:
|
/s/ Gui Hua Lan
|
|
|
|
|
Name:
Gui Hua Lan
|
|
|
|
|
Title:
Chief Executive Officer and Chairman of the Board
|
|
|
|
|
|
|
China Shenghuo Pharmaceutical Holdings, (AMEX:KUN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
China Shenghuo Pharmaceutical Holdings, (AMEX:KUN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
